Ranbaxy has received an Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its New-Jersey based Ohm Laboratories. An EIR signifies that all issues and concerns of non-compliance observed by the FDA in its December audits have been rectified satisfactorily.
Ohm Labs is currently the only facility certified for this purpose as Ranbaxy’s other units at Paonta Sahib, Dewas and Mohali (all in India) have been barred following deviations from compliance norms.
Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
